Blood Cancer: Myths Vs Facts - Experts Bust 10 Common Misconceptions About Diagnosis, Risk & Treatment

  

Blood cancer, or hematologic malignancy, is often surrounded by misconceptions that delay diagnosis and treatment. From the belief that it’s always inherited or contagious, to myths around stem cell transplants and alternative cures, misinformation can cost precious time and hope. To bring clarity, Dr Chepsy C Philip, Clinical Hematology & Bone Marrow Transplant Physician at Believers Church Medical College Hospital, Thiruvalla, debunks the most common myths about blood cancer and shares the truth about how it can be detected, treated, and even cured with today’s advanced therapies. 

Myth 1: Blood cancer is always an inherited disease. 

Fact: While blood cancer results from acquired genetic changes, most cases are not inherited. Environmental exposures and random mutations are often the cause.  

Myth 2: Blood cancer affects older people 

Fact: Dr Philip says, "All age groups, including Children, young adults, and the elderly, are susceptible to blood cancer." 

Myth 3: Blood cancer spreads from person to person.
 
Fact: Blood cancer is not contagious, as it develops inside the body and poses no risk of being contagious.  

Myth 4: A Blood test is sufficient to detect blood cancer 

Fact: "Blood tests can show abnormalities, but a diagnosis often requires a bone marrow biopsy, imaging and gene testing," reveals Dr Philip.

Myth 5: You cannot have blood cancer if you look healthy. 

Fact: There are tendencies to overlook the common symptoms of blood cancers, such as persistent fatigue, unexplained weight loss, recurring fever, and night sweats. While such symptoms may not seem severe, preventive measures, such as routine blood tests, often help reveal the onset of the disease, allowing for early intervention in such cases. 

Myth 6: There is no hope once a patient is diagnosed with blood cancer. 

Fact: There are living examples worldwide where survivors have overcome or survived blood cancer. Advanced therapies, including immunotherapy, targeted therapy, CAR-T cells, and blood stem cell transplants, have improved survival rates and significantly enhanced the quality of life.  

Myth 7: Blood cancer can be cured with alternative medicine. 

Fact: Evidence-based therapies are beneficial in treating blood cancer. It is essential to note that alternative remedies may offer comfort but cannot replace medical treatments that are already proven to have better patient outcomes.  

Myth 8: Blood cancers spread quickly in all patients. 

Fact: Dr Philip says, "Not all types of blood cancer progress rapidly; for example, lymphoma may grow slowly and remain stable for years. Having said that, leukemia progresses rapidly. So it is not right to club all types of blood cancers to progress quickly in patients."

Myth 9: Blood cancer is just one disease. 

Fact: There are different types of blood cancer, including leukemia, lymphoma, and multiple myeloma. 

Myth 10: A blood stem cell transplant is risky and rarely successful. 

Fact: Blood stem cell transplants have enough evidence to potentially give someone with blood cancer and blood disorders a second chance at life. This treatment method has a proven track record, with success rates continually improving patient outcomes.  

 

 

This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   

https://gscrochetdesigns.blogspot.com. one can see my crochet creations  
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement
https://GSiyers home remedies.blogspot.com   is the latest addition to my blogs

 

11 Cutting-Edge Cancer Treatments Expected in 2025 /

Cancer has long been one of the most complex diseases to treat, constantly evolving to resist therapies and spread aggressively. While traditional treatments like chemotherapy and radiation have been the backbone of cancer care, new research continues to push the boundaries of what’s possible. As a result, global cancer mortality rates have declined by one-third since 1991, and with more cutting-edge therapies on the horizon, 2025 is shaping up to be another promising year for oncology breakthroughs.

 

1. Expanding the reach of cancer drug development

The past few years have seen a rise in experimental treatments targeting molecules once thought to be impossible to reach. KRAS mutations, long considered untouchable by conventional drugs, have seen a breakthrough with the development of inhibitors like sotorasib. New candidates, such as divarasib, are now in trials with the goal of improving on current treatments.

GPCRs (G protein-coupled receptors) are also gaining attention beyond KRAS. These cell surface proteins play an essential role in cancer development, yet more than half of them have been classified as difficult to target. Experts believe that ongoing work by biotech firms developing GPCR-based therapies will lead to meaningful progress this year. 

 

Another emerging approach is the use of molecular glues—small molecules that bring two proteins together to trigger targeted protein degradation. While most molecular glue therapies remain in the early stages of testing, researchers anticipate that 2025 will bring deeper insights into their potential, laying the groundwork for future clinical applications.

 

 

2. The continued rise of immunotherapy

Immunotherapy has been a game changer in cancer treatment, and it’s set to remain at the forefront of research. Monoclonal antibodies, such as Imfinzi, have shown promise in treating small-cell lung cancer, with experts noting its recent recommendation for approval in the European Union. By blocking the PD-L1 protein in cancer cells, this therapy enables the immune system to better recognize and attack tumors. 

 

T cell-based immunotherapies will also continue to evolve, with scientists predicting that innate immune cells—those that naturally regulate T cell responses—will play a larger role in the next generation of cancer treatments. Some believe that advancements in this area could lead to novel cancer vaccines that improve immune responses and broaden the range of treatable cancers. 

 

While cancer vaccines remain challenging to develop due to the way tumors evade the immune system, researchers are making strides in integrating them with immune checkpoint inhibitors, such as pembrolizumab. This combination approach is showing promise in boosting the body’s ability to fight tumors, offering hope for more effective long-term treatment strategies. 

 

3. Bispecific antibodies gaining traction 

Bispecific antibodies—drugs that can target two different antigens at once—are becoming an increasingly important part of oncology trials. The FDA recently approved several bispecific antibody therapies, and experts predict that this class of drugs will continue expanding into new treatment areas in 2025. Researchers are particularly focused on optimizing dosing strategies and exploring the potential of bispecifics in treating solid tumors, which could make them an essential part of future cancer care.

 

4. B cells and personalized cancer treatments

As researchers seek to develop more tailored cancer therapies, B cells are emerging as a promising avenue for drug development. Experts suggest that B cells not only generate antibodies that can recognize tumors but also help coordinate immune responses against them. Scientists are now working to develop treatments that harness these cells to target cancerous tissues while leaving healthy cells unharmed. This personalized approach could pave the way for more precise, less toxic treatment options in the years to come. Related: Lung Cancer Pill Cuts Risk of Death by 50% 

 

5. Cyclic peptides and the future of targeted therapy 

Another area of interest in cancer research is the development of cyclic peptides, a new class of targeted therapies. These compounds form a closed-loop structure that enables them to bind more effectively to cancer cell receptors, potentially disrupting tumor growth. Pharmaceutical companies have taken notice, with major deals being signed to accelerate the clinical development of cyclic peptide drugs. Many believe that these compounds represent the next big wave of cancer drug discovery, offering another tool in the fight against the disease.

6. Refining anti-angiogenesis therapy  

For over 20 years, anti-angiogenesis therapies have been used to slow tumor growth by cutting off their blood supply. While these treatments have been beneficial, their effectiveness has been restricted by side effects. Researchers are now focused on developing improved versions that specifically target cancer cells while reducing harm to healthy tissues. Experts believe these refinements will allow patients to tolerate the medications better, leading to longer treatment durations and improved survival rates. With ongoing advancements, these therapies may soon become a more reliable component of cancer care. 

 

7. Antibody-drug conjugates (ADCs) advancing further 

ADCs have gained attention as a promising tool in cancer treatment, delivering potent drugs directly to cancer cells while sparing healthy tissue. There are now more than 100 ADC candidates being evaluated in clinical trials, with continuous improvements in drug potency and targeting mechanisms. Researchers believe these therapies will soon become a more widely used alternative to traditional chemotherapy, offering effective and less toxic options for patients. With further refinements, ADCs are expected to play an even greater role in personalized cancer treatment.

8. Increased investment in neglected cancers

Certain types of cancer, including pancreatic, brain, and stomach cancer, have historically received less research funding than more common cancers like breast and lung cancer. However, this trend is shifting. More resources are being allocated to finding new treatments, leading to promising advancements. In 2025, the availability of gene therapies for sickle cell disease is expected to increase, and researchers are making strides in CAR T cell therapy for aggressive brain tumors. These developments offer hope for patients with conditions that have long been difficult to treat. 

 

 

9. Understanding the link between diabetes and cancer

Recent studies suggest that metabolic disorders like diabetes may be closely linked to cancer development. Researchers are investigating how better blood sugar control could reduce the risk of certain cancers. Some experts believe that diabetes drugs like GLP-1 receptor agonists could also play a role in cancer prevention. Ongoing research aims to determine whether improving metabolic health can lower cancer risks and improve patient outcomes. These findings could open new doors for prevention strategies and more targeted treatments. 

 

 

10. Unraveling the microbiome-cancer connection 

The trillions of microbes in the human body play a crucial role in overall health, including cancer progression and treatment response. Scientists are now studying how gut bacteria influence the effectiveness of cancer therapies. Early research suggests that microbiome composition and fiber intake may impact the success of immunotherapies and stem cell transplants. To better understand these connections, researchers are building large biorepositories to analyze microbiome samples. The goal is to develop more personalized treatments that take gut health into account, potentially improving patient outcomes. 

 

 

11. New strategies for early cancer detection 

 

Cancer diagnoses in younger adults have been on the rise, making early detection more important than ever. Advances in liquid biopsy technology are offering new ways to identify cancer at its earliest stages. These tests can detect cancer-related genetic material in blood samples, potentially leading to quicker diagnoses and better treatment outcomes. Experts believe that widespread adoption of these screening methods could be a game-changer in catching cancers before they progress to more advanced stages.

This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   

https://gscrochetdesigns.blogspot.com. one can see my crochet creations  
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement
https://GSiyers home remedies.blogspot.com   is the latest addition to my blogs

11 Cutting-Edge Cancer Treatments Expected in 2025

Cancer has long been one of the most complex diseases to treat, constantly evolving to resist therapies and spread aggressively. While traditional treatments like chemotherapy and radiation have been the backbone of cancer care, new research continues to push the boundaries of what’s possible. As a result, global cancer mortality rates have declined by one-third since 1991, and with more cutting-edge therapies on the horizon, 2025 is shaping up to be another promising year for oncology breakthroughs. 

 

1. Expanding the reach of cancer drug development

The past few years have seen a rise in experimental treatments targeting molecules once thought to be impossible to reach. KRAS mutations, long considered untouchable by conventional drugs, have seen a breakthrough with the development of inhibitors like sotorasib. New candidates, such as divarasib, are now in trials with the goal of improving on current treatments.

GPCRs (G protein-coupled receptors) are also gaining attention beyond KRAS. These cell surface proteins play an essential role in cancer development, yet more than half of them have been classified as difficult to target. Experts believe that ongoing work by biotech firms developing GPCR-based therapies will lead to meaningful progress this year. 

 

Another emerging approach is the use of molecular glues—small molecules that bring two proteins together to trigger targeted protein degradation. While most molecular glue therapies remain in the early stages of testing, researchers anticipate that 2025 will bring deeper insights into their potential, laying the groundwork for future clinical applications. 

 

2. The continued rise of immunotherapy

Immunotherapy has been a game changer in cancer treatment, and it’s set to remain at the forefront of research. Monoclonal antibodies, such as Imfinzi, have shown promise in treating small-cell lung cancer, with experts noting its recent recommendation for approval in the European Union. By blocking the PD-L1 protein in cancer cells, this therapy enables the immune system to better recognize and attack tumors. 

 

T cell-based immunotherapies will also continue to evolve, with scientists predicting that innate immune cells—those that naturally regulate T cell responses—will play a larger role in the next generation of cancer treatments. Some believe that advancements in this area could lead to novel cancer vaccines that improve immune responses and broaden the range of treatable cancers. 

 

While cancer vaccines remain challenging to develop due to the way tumors evade the immune system, researchers are making strides in integrating them with immune checkpoint inhibitors, such as pembrolizumab. This combination approach is showing promise in boosting the body’s ability to fight tumors, offering hope for more effective long-term treatment strategies. 

 

3. Bispecific antibodies gaining traction 

Bispecific antibodies—drugs that can target two different antigens at once—are becoming an increasingly important part of oncology trials. The FDA recently approved several bispecific antibody therapies, and experts predict that this class of drugs will continue expanding into new treatment areas in 2025. Researchers are particularly focused on optimizing dosing strategies and exploring the potential of bispecifics in treating solid tumors, which could make them an essential part of future cancer care.

4. B cells and personalised cancer treatments

 As researchers seek to develop more tailored cancer therapies, B cells are emerging as a promising avenue for drug development. Experts suggest that B cells not only generate antibodies that can recognize tumors but also help coordinate immune responses against them. Scientists are now working to develop treatments that harness these cells to target cancerous tissues while leaving healthy cells unharmed. This personalized approach could pave the way for more precise, less toxic treatment options in the years to come.

5. Cyclic peptides and the future of targeted therapy 

Another area of interest in cancer research is the development of cyclic peptides, a new class of targeted therapies. These compounds form a closed-loop structure that enables them to bind more effectively to cancer cell receptors, potentially disrupting tumor growth. Pharmaceutical companies have taken notice, with major deals being signed to accelerate the clinical development of cyclic peptide drugs. Many believe that these compounds represent the next big wave of cancer drug discovery, offering another tool in the fight against the disease. 

 

6. Refining anti-angiogenesis therapy 

For over 20 years, anti-angiogenesis therapies have been used to slow tumor growth by cutting off their blood supply. While these treatments have been beneficial, their effectiveness has been restricted by side effects. Researchers are now focused on developing improved versions that specifically target cancer cells while reducing harm to healthy tissues. Experts believe these refinements will allow patients to tolerate the medications better, leading to longer treatment durations and improved survival rates. With ongoing advancements, these therapies may soon become a more reliable component of cancer care. 

 

7. Antibody-drug conjugates (ADCs) advancing further  

ADCs have gained attention as a promising tool in cancer treatment, delivering potent drugs directly to cancer cells while sparing healthy tissue. There are now more than 100 ADC candidates being evaluated in clinical trials, with continuous improvements in drug potency and targeting mechanisms. Researchers believe these therapies will soon become a more widely used alternative to traditional chemotherapy, offering effective and less toxic options for patients. With further refinements, ADCs are expected to play an even greater role in personalized cancer treatment.

8. Increased investment in neglected cancers

 

Certain types of cancer, including pancreatic, brain, and stomach cancer, have historically received less research funding than more common cancers like breast and lung cancer. However, this trend is shifting. More resources are being allocated to finding new treatments, leading to promising advancements. In 2025, the availability of gene therapies for sickle cell disease is expected to increase, and researchers are making strides in CAR T cell therapy for aggressive brain tumors. These developments offer hope for patients with conditions that have long been difficult to treat.

 

9. Understanding the link between diabetes and cancer
Recent studies, suggest that metabolic disorders like diabetes may be closely linked to cancer development. Researchers are investigating how better blood sugar control could reduce the risk of certain cancers. Some experts believe that diabetes drugs like GLP-1 receptor agonists could also play a role in cancer prevention. Ongoing research aims to determine whether improving metabolic health can lower cancer risks and improve patient outcomes. These findings could open new doors for prevention strategies and more targeted treatments. 

 

10. Unraveling the microbiome-cancer connection   

The trillions of microbes in the human body play a crucial role in overall health, including cancer progression and treatment response. Scientists are now studying how gut bacteria influence the effectiveness of cancer therapies. Early research suggests that microbiome composition and fiber intake may impact the success of immunotherapies and stem cell transplants. To better understand these connections, researchers are building large biorepositories to analyze microbiome samples. The goal is to develop more personalized treatments that take gut health into account, potentially improving patient outcomes. 

 

11. New strategies for early cancer detection

Cancer diagnoses in younger adults have been on the rise, making early detection more important than ever. Advances in liquid biopsy technology are offering new ways to identify cancer at its earliest stages. These tests can detect cancer-related genetic material in blood samples, potentially leading to quicker diagnoses and better treatment outcomes. Experts believe that widespread adoption of these screening methods could be a game-changer in catching cancers before they progress to more advanced stages.

This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   

https://gscrochetdesigns.blogspot.com. one can see my crochet creations  
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement
https://GSiyers home remedies.blogspot.com   is the latest addition to my blogs.

A targeted therapy to treat inflammatory bowel disease

The biomedical scientists of the University of California, Riverside have found a way for drugs to be more effective against inflammatory bowel disease/ IBD.

IBD, a chronic inflammatory disease of the intestine, includes Crohn’s disease and ulcerative colitis. It is commonly treated with one of several available biological drugs that block an inflammatory molecule called Tumour Necrosis Factor Alpha or TNF-alpha, from binding to two receptors, TNFR1 and TNFR2. Only about 50 % of patients are helped long term by this treatment.

TNF-alpha does drive much of the inflammation and tissue destruction in IBD, said a distinguished Prof., who led the study.

It’s why it is targeted by drugs. Our interest in this study was to look for a more targeted therapy that might have better impact than the existing approach, which is to block all TNF-alpha, he added.

The Prof. explained that people have 2 different receptors, TNFR1 & TNFR2, in each of their cells that bind TNF-alpha. Currently, TNF-alpha-targeted drugs block both TNFR1 & TNFR2. His experiments were done in mice, which have the same 2 receptors. The pattern of inflammation in mice is similar to that seen in humans.

TNF-alpha, produced by the body’s cells, also induced specialized immune and other cells, which both promote inflammation and suppressed it. Thus, TNF-alpha played a role in the destruction and the healing of tissues—a double-edged sword. He said evidence existed that TNFR1 may be driving most of the destructive effects of IBD, and whereas TNFR2 may drive the healing and restorative effects.

If you block both the receptors, you block the destructive effects and the recovery, he said.

To circumvent this, in our work we opted to do selective targeting of TNFR1, he explained.

His group was encouraged by 2 pieces of evidence suggesting that targeting TNFR1 maybe a more beneficial strategy, the researchers used a reagent from Inmune Bio, a biotechnology company that was selective for blocking TNFR1. Mice treated with this reagent were found to benefit from it. The researchers also did genetic targeting of TNFR1 to reduce its signaling. The impact, they found, was dramatic.

When we reduced TNFR1 signalling, the mice showed a significant benefit relative to mice who had the full level of TNFR1 signalling, the Prof. said.

This approach may offer more opportunity to TNFR2 to contribute to the healing, he added.

According to the Prof., mice that have a genetic deficiency in TNFR2 got much more severe disease, suggesting that TNFR2 does indeed have beneficial effects.

Without TNFR2, IBD is a lot worse, he said.

Several diseases, such as rheumatoid arthritis, multiple sclerosis, and psoriasis, are related to the action of TNF-alpha, indeed, different tissues in the body are differently sensitive to the effects of TNF-alpha. The role of the receptors TNFR1 and TNFR2 varied in the different tissues.

TNF-alpha is a very common way in which your body reacts to inflammatory triggers, such as infection, he said.

This protein can mediate several processes in the body to promote inflammation. The inflammation arises to clear an infection or kill a tumour. But in autoimmune diseases, the same inflammation and tissue damage that TNF-alpha provokes are what drive the disease. In other words, you want TNF-alpha at the right time to knock off a certain infection but once that is accomplished, you don’t want this protein to be around any longer. Many diseases are linked to TNF-alpha lingering in tissues, he added.

The prof. said the current research was a combination of testing approved drugs that are used in the clinic as well as examining more detailed questions related to the mechanisms of disease and protection.

It’s about continuously finding better cutting-edge drugs and better targets to treat disease, he said.

This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   

https://gscrochetdesigns.blogspot.com. one can see my crochet creations  
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement